MX2011008791A - Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. - Google Patents
Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion.Info
- Publication number
- MX2011008791A MX2011008791A MX2011008791A MX2011008791A MX2011008791A MX 2011008791 A MX2011008791 A MX 2011008791A MX 2011008791 A MX2011008791 A MX 2011008791A MX 2011008791 A MX2011008791 A MX 2011008791A MX 2011008791 A MX2011008791 A MX 2011008791A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant virus
- replication deficient
- cytotoxic
- deficient recombinant
- response against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un virus recombinante deficiente en replicación que codifica por lo menos un antígeno y/o epítopo antigénico, en donde la expresión del antígeno y/o epítopo antigénico es regulada por un elemento de control transcripcional que comprende por lo menos dos elementos que impulsan la expresión temprana del antígeno y/o epítopo antigénico y el uso del virus recombinante deficiente en replicación como medicamento o vacuna.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15985709P | 2009-03-13 | 2009-03-13 | |
EP09009759 | 2009-07-28 | ||
PCT/EP2010/001545 WO2010102822A1 (en) | 2009-03-13 | 2010-03-11 | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011008791A true MX2011008791A (es) | 2011-09-29 |
Family
ID=42115708
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015004592A MX355366B (es) | 2009-03-13 | 2010-03-11 | Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. |
MX2011008791A MX2011008791A (es) | 2009-03-13 | 2010-03-11 | Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015004592A MX355366B (es) | 2009-03-13 | 2010-03-11 | Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. |
Country Status (17)
Country | Link |
---|---|
US (1) | US8394385B2 (es) |
EP (2) | EP3456349A1 (es) |
JP (2) | JP2012520061A (es) |
KR (1) | KR101752737B1 (es) |
CN (1) | CN102341120B (es) |
AU (1) | AU2010223524A1 (es) |
BR (1) | BRPI1009138B1 (es) |
CA (1) | CA2751301C (es) |
EA (1) | EA023832B1 (es) |
HK (1) | HK1161677A1 (es) |
IL (1) | IL213572B (es) |
MX (2) | MX355366B (es) |
MY (1) | MY156997A (es) |
NZ (1) | NZ593525A (es) |
SG (2) | SG172115A1 (es) |
WO (1) | WO2010102822A1 (es) |
ZA (1) | ZA201106655B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8613936B2 (en) | 2009-03-13 | 2013-12-24 | Bavarian Nordic A/S | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
AU2015203893A1 (en) * | 2009-03-13 | 2015-08-06 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |
US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
NZ608143A (en) | 2010-10-15 | 2015-02-27 | Bavarian Nordic As | Recombinant modified vaccinia virus ankara (mva) influenza vaccine |
EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
US10111946B2 (en) * | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
JP6505016B2 (ja) * | 2012-10-28 | 2019-04-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 強靭なt細胞用のpr13.5プロモータ及び抗体応答 |
EP3119831B1 (en) | 2014-03-21 | 2019-10-02 | Furanix Technologies B.V | Polyesters comprising 2,5-furandicarboxylate and saturated diol units having a high glass transition temperature |
KR20160140075A (ko) | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
PL3407910T3 (pl) | 2016-01-29 | 2022-08-16 | Bavarian Nordic A/S | Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni |
MX2018013340A (es) | 2016-05-02 | 2019-08-21 | Janssen Vaccines & Prevention Bv | Combinaciones de vacunas terapeuticas para el vph. |
JP7062003B2 (ja) | 2016-09-28 | 2022-05-02 | バヴァリアン・ノルディック・アクティーゼルスカブ | ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 |
WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
CN110168092A (zh) | 2016-12-28 | 2019-08-23 | 特朗斯吉有限公司 | 溶瘤病毒和治疗分子 |
US11548980B2 (en) | 2017-05-18 | 2023-01-10 | Avantium Knowledge Centre B.V. | Polyester copolymer |
EP3625284A1 (en) | 2017-05-18 | 2020-03-25 | Avantium Knowledge Centre B.V. | Polyester copolymer |
BR112019026126A2 (pt) | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
JP7202362B2 (ja) | 2017-08-24 | 2023-01-11 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えmva及び抗体の静脈内投与を用いた、がん治療のための併用療法 |
KR20200100745A (ko) | 2017-12-19 | 2020-08-26 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | B형 간염 바이러스(hbv)에 대한 면역 반응 유도를 위한 방법 및 조성물 |
WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
JP2022512595A (ja) | 2018-10-05 | 2022-02-07 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
EP3883599A1 (en) | 2018-11-20 | 2021-09-29 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
WO2020106144A1 (en) | 2018-11-22 | 2020-05-28 | Avantium Knowledge Centre B.V. | Process for the production of one or more polyester copolymers, method for the preparation of one or more oligomers, oligomer composition and polyester copolymer |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
KR20220106775A (ko) | 2019-11-20 | 2022-07-29 | 버베리안 노딕 에이/에스 | 암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스 |
EP3928789A1 (en) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
EP4108257A1 (en) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |
EP4358999A1 (en) | 2021-06-23 | 2024-05-01 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
WO2023135313A1 (en) * | 2022-01-17 | 2023-07-20 | Nouscom Ag | Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024038175A1 (en) | 2022-08-18 | 2024-02-22 | Transgene | Chimeric poxviruses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
EP0243029A1 (en) | 1986-04-08 | 1987-10-28 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Recombinant vaccinia virus expressing human retrovirus gene |
US5747324A (en) | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
CA2104649A1 (en) | 1992-08-25 | 1994-02-26 | Makoto Seki | Antisense compounds complementary to hcv genome |
CN100537773C (zh) | 2000-11-23 | 2009-09-09 | 巴法里安诺迪克有限公司 | 改良安卡拉痘苗病毒变体 |
BR0214822A (pt) | 2001-12-10 | 2004-12-14 | Bavarian Nordic As | Formulações contendo poxvìrus e processo para preparar composições contendo poxvìrus estáveis |
KR20040108804A (ko) * | 2002-05-16 | 2004-12-24 | 버베리안 노딕 에이/에스 | 우두 ati 프로모터를 사용하는 것에 의한 변형백시니아 바이러스 안카라에서 유전자의 발현 |
EA012723B1 (ru) * | 2002-11-25 | 2009-12-30 | Бавариан Нордик А/С | Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение |
EP1845164B1 (en) | 2003-11-24 | 2010-06-16 | Bavarian Nordic A/S | Promoters for expression in modified vaccinia virus ankara |
US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
-
2010
- 2010-03-09 US US12/719,987 patent/US8394385B2/en active Active
- 2010-03-11 NZ NZ593525A patent/NZ593525A/xx unknown
- 2010-03-11 EP EP18195933.9A patent/EP3456349A1/en active Pending
- 2010-03-11 EA EA201171128A patent/EA023832B1/ru not_active IP Right Cessation
- 2010-03-11 JP JP2011553357A patent/JP2012520061A/ja active Pending
- 2010-03-11 AU AU2010223524A patent/AU2010223524A1/en not_active Abandoned
- 2010-03-11 EP EP10708732A patent/EP2405939A1/en not_active Ceased
- 2010-03-11 BR BRPI1009138-6A patent/BRPI1009138B1/pt active IP Right Grant
- 2010-03-11 CN CN201080010990.7A patent/CN102341120B/zh active Active
- 2010-03-11 CA CA2751301A patent/CA2751301C/en active Active
- 2010-03-11 SG SG2011042967A patent/SG172115A1/en unknown
- 2010-03-11 WO PCT/EP2010/001545 patent/WO2010102822A1/en active Application Filing
- 2010-03-11 MX MX2015004592A patent/MX355366B/es unknown
- 2010-03-11 SG SG10201400593VA patent/SG10201400593VA/en unknown
- 2010-03-11 MX MX2011008791A patent/MX2011008791A/es active IP Right Grant
- 2010-03-11 MY MYPI2011002771A patent/MY156997A/en unknown
- 2010-03-11 KR KR1020117024016A patent/KR101752737B1/ko active IP Right Grant
-
2011
- 2011-06-15 IL IL213572A patent/IL213572B/en active IP Right Grant
- 2011-09-12 ZA ZA2011/06655A patent/ZA201106655B/en unknown
-
2012
- 2012-03-02 HK HK12102153.5A patent/HK1161677A1/zh unknown
-
2015
- 2015-06-02 JP JP2015111927A patent/JP6130876B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2010102822A1 (en) | 2010-09-16 |
IL213572B (en) | 2018-05-31 |
IL213572A0 (en) | 2011-07-31 |
MY156997A (en) | 2016-04-15 |
CA2751301A1 (en) | 2010-09-16 |
EP3456349A1 (en) | 2019-03-20 |
MX355366B (es) | 2018-04-17 |
JP6130876B2 (ja) | 2017-05-17 |
CA2751301C (en) | 2018-05-01 |
NZ593525A (en) | 2012-12-21 |
KR101752737B1 (ko) | 2017-06-30 |
BRPI1009138B1 (pt) | 2022-04-05 |
EA023832B1 (ru) | 2016-07-29 |
SG10201400593VA (en) | 2014-06-27 |
US8394385B2 (en) | 2013-03-12 |
CN102341120A (zh) | 2012-02-01 |
EA201171128A1 (ru) | 2012-08-30 |
SG172115A1 (en) | 2011-07-28 |
US20100233203A1 (en) | 2010-09-16 |
AU2010223524A1 (en) | 2011-07-07 |
ZA201106655B (en) | 2014-12-23 |
JP2012520061A (ja) | 2012-09-06 |
EP2405939A1 (en) | 2012-01-18 |
HK1161677A1 (zh) | 2012-08-03 |
CN102341120B (zh) | 2016-05-18 |
JP2015180216A (ja) | 2015-10-15 |
BRPI1009138A2 (pt) | 2016-03-08 |
KR20110129954A (ko) | 2011-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX355366B (es) | Promotor temprano-tardio optimizado combinado con vacunacion repetida que favorece la respuesta de celulas t citotoxicas contra antigenos en vacunas de virus recombinantes deficientes en replicacion. | |
IL263249B (en) | A polypeptide isolated from btv virus which causes an immune response in an animal and a polypeptide containing a DNA segment that codes for an epitope or an antigenic determinant of the btv polypeptide | |
MX2015008847A (es) | Composiciones inmunogenicas de virus de influenza y usos de las mismas. | |
TN2017000133A1 (en) | Modified virus-like particles of cmv | |
BR112014020019A2 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes | |
TR201903223T4 (tr) | Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. | |
EP4272750A3 (en) | Protein antigens that provide protection against pneumococcal colonization and/or disease | |
MX351643B (es) | Antigeno ndv recombinante y usos del mismo. | |
CA2763359C (en) | New human rotavirus strains and vaccines | |
EA201590829A1 (ru) | Новые мукозные адъюванты и системы доставки | |
MY159543A (en) | Recombinant avian influenza vaccine and uses thereof | |
MD20120127A2 (en) | Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV | |
WO2010040847A3 (en) | Recombinant protein bodies as immunogen-specific adjuvants | |
WO2016130560A3 (en) | Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats | |
WO2012118559A3 (en) | Tetravalent and mixed head bivalent dengue vaccine | |
CL2012003219A1 (es) | Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal. | |
NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
BR112014023283A8 (pt) | Composição imunogênica, segunda composição imunogênica, e, método para prevenção e/ou tratamento contra doença influenza | |
WO2010080188A3 (en) | Epitope targeted anthrax vaccine | |
WO2013173256A3 (en) | New and improved influenza vaccines | |
WO2012178078A3 (en) | Use of yscf, truncated yscf and yscf homologs as adjuvants | |
AR078147A1 (es) | Regimen de inmunizacion por sensibilizacion - refuerzo heterologa | |
Dias et al. | Study of the immune response induced by different adjuvants | |
TN2010000479A1 (en) | Inactivated live - attenuated bluetongue virus vaccine | |
WO2008100142A3 (en) | Vaccine formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |